Drug intelligence / Profile preview

VXN-NEO

Development stage: Unknown
Lead developer: Vaxinano
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

VXN-NEO is an inactivated whole-pathogen nanoparticle vaccine developed by Vaxinano for the prevention of neosporosis in cattle. The vaccine utilizes the proprietary STELLAR-NP platform, which consists of non-toxic, biodegradable, starch-based nanoparticles that encapsulate the inactivated *Neospora caninum* pathogen. This technology is designed to induce a robust, cross-protective immune response without the need for traditional chemical adjuvants. Neosporosis is a major cause of bovine abortion and significant economic losses in the dairy and beef industries, and VXN-NEO represents a novel approach to controlling this parasitic infection.

Beyond the preview

Go deeper on VXN-NEO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VXN-NEO.

Explore the full profile